ISRCTN63491981已完成不适用
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in primary immunodeficiency diseases
Octapharma AG (Switzerland)0 个研究点目标入组 45 人开始时间: 2008年12月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age of greater than or equal to 2 years and less than or equal to 75 years, either sex
- •2. For minor patients, above a minimum weight based on the amount of blood required for testing: per individual, the trial-related blood loss (including any losses in the manoeuvre) should not exceed 3% of the total blood volume during a period of four weeks and should not exceed 1% at any single time (the total volume of blood is estimated at 80 ml/kg body weight)
- •3. Confirmed diagnosis of primary immunodeficiency as stated by the World Health Organization and requiring immunoglobulin replacement therapy. The exact type of PID should be recorded.
- •4. Previously treated with commercial Octagam® 5% every 21 - 28 days for at least six infusion intervals at a constant dose of 300 - 600 mg/kg body weight
- •5. Availability of the IgG trough levels of the two previous infusions before enrolment, and maintenance of at least 5.5 g/L in the trough levels of these two infusions
- •6. Negative result on a pregnancy test (human chorionic gonadotropin [HCG]-based assay in blood or urine) for women of child-bearing potential and use of a reliable method of contraception for the duration of the study
- •7. For adult patients: freely given written informed consent. For minor patients: freely given written informed consent from both parents/legal guardians and written informed assent from the child/adolescent greater than or equal to 8 years of age according to his/her age and capacity of understanding
- •8. Willingness to comply with all aspects of the protocol, including blood sampling, for the duration of the study
排除标准
- •1. Acute infection requiring intravenous antibiotic treatment within two weeks before screening
- •2. Known history of adverse reactions to IgA in other products
- •3. Exposure to blood or any blood product or derivative, other than commercially available Octagam® 5%, within the past 3 months
- •4. Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived products, or any component of the investigational product, such as maltose
- •5. Requirement of any routine premedication for IGIV infusion
- •6. History of congenital impairment of pulmonary function
- •7. Severe liver function impairment (alanine aminotransferase [ALAT] 3 x greater than normal value)
- •8. Severe renal function impairment (creatinine greater than 120 µmol/L), or predisposition for acute renal failure (e.g. any degree of pre-existing renal insufficiency or routine treatment with known nephritic drugs)
- •9. History of autoimmune haemolytic anaemia
- •10. History of diabetes mellitus
- •11. Congestive heart failure New York Heart Association (NYHA) grade III or IV
- •12. Non-controlled arterial hypertension (systolic blood pressure greater than 160 mmHg and/or diastolic blood pressure greater than 90 mmHg)
- •13. History of deep vein thrombosis (DVT) or thrombotic complications of IGIV therapy
- •14. Known to be infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)
- •15. Presence of any clinically relevant disease or unstable condition beside those concerning study indication at screening which in the opinion of the investigator may interfere with the conduct of the study
- •16. Treatment with steroids, immunosuppressive or immunomodulatory drugs
- •17. Planned vaccination during the study period
- •18. Treatment with any investigational agent within the prior 3 months
- •19. Known or suspected to abuse alcohol, drugs, psychotropic agents or other chemicals within the last 12 months
- •20. Pregnant and/or nursing women
研究者
相似试验
进行中（未招募）
1 期
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1 Level: LLT Classification code 10064859 Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-GBOctapharma AG5
进行中（未招募）
1 期
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immunodeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-FROctapharma AG5
进行中（未招募）
不适用
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-DEOctapharma AG45
已完成
1 期
A clinical study to evaluate efficacy, safety and tolerability of ISN001 in dystrophic epidermolysis bullosa patients.dystrophic epidermolysis bullosaJPRN-UMIN000028366Ishin Pharmaceutical Co. Ltd.5
已完成
2 期
se of Roselle in Bronchial asthma and MalnutritioCTRI/2020/08/027013DXN Manufacturing India Pvt Ltd12